Pregabalin Capsule
Product Images NDC 70518-4749

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4749). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin Capsule C-V 200 mg oral capsules packaging label showing quantity of 30 capsules. The label includes the NDC number 70518-4749-00, states the capsule color as orange, and indicates the product is repackaged by RemedyRepack Inc. Additional storage and federal caution information is present, along with manufacturer details for Camber Pharma, Inc.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing the percent of patients improved plotted against the percent improvement in pain from baseline. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and a placebo group. The y-axis represents the percent of patients improved, and the x-axis represents percent improvement in pain from baseline.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A line graph comparing the estimated percentage of subjects without LTR (likely loss to response) over 180 days for Pregabalin versus Placebo groups. The y-axis shows percentage from 0 to 100%, and the x-axis shows time in days, with Pregabalin showing higher survival without LTR than Placebo over the period.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph depicting the percent of subjects improved over time from baseline to Week 12 using the RCOF measure. The x-axis shows percent improvement, while the y-axis indicates the percent of subjects improved. Two curves represent Pregabalin and Placebo groups, with Pregabalin showing higher improvement percentages compared to Placebo throughout the duration.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph comparing the percentage of subjects improved over a range from 0 to 100 percent improvement from baseline to week 16 BOCF. The graph shows two lines: one solid line for Pregabalin and one dashed line for Placebo, indicating the proportion of subjects improved by each treatment.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph comparing the percent of patients improved to percent improvement in pain from baseline, showing two lines: one for Pregabalin 100 mg three times a day and one for placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis represents percent of patients improved, with markers at intervals up to 100%.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph depicting percent of patients improved against percent improvement in pain from baseline. The graph compares Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, alongside placebo. Percent of patients improved is shown on the vertical axis, and percent improvement in pain from baseline on the horizontal axis.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It includes three lines representing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing the relationship between dosage and patient improvement over a range of pain improvement percentages.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, indicating patient pain improvement over a range from 0 to 100 percent.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar chart comparing responder rates (%) across different dosage groups in two studies, Study E1 and Study E3. Study E1 shows increasing responder rates from placebo to 600 mg/day doses, all administered BID. Study E3 compares placebo to 600 mg/day doses administered BID and TID, with higher responder rates in the active treatment groups. Statistical significance to placebo is indicated for certain doses.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A line graph showing median percentage change in seizure reduction from baseline plotted against dose (mg/day). The graph includes data points from four studies labeled E1 BID, E2 TID, E3 BD, and E3 TID, each represented by different symbols. P-values indicating statistical significance are displayed near some data points. The x-axis ranges from 0 to 600 mg/day, and the y-axis represents seizure reduction up to 60 percent. A note indicates the placebo dose is zero and only significant p-values are shown.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A bar chart showing responder rates (%) for Pregabalin at dosages of 2.5 mg/kg/day and 10 mg/kg/day compared to a placebo. The chart includes sample sizes: 93 for placebo, 103 for 2.5 mg/kg/day, and 96 for 10 mg/kg/day. Responder rates increase from placebo (22.6%) to 2.5 mg/kg/day (29.1%) and 10 mg/kg/day (40.6%).*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph depicting the percentage of patients improved relative to the percent improvement in pain from baseline. It includes four lines representing Pregabalin doses of 600 mg, 450 mg, 300 mg daily, and placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows percent of patients improved.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure diagram of Pregabalin showing its molecular arrangement with labeled nitrogen (NH2), oxygen (O), and carbon (CH3) groups indicating its composition as an amino acid derivative.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.